Scarica l'app Stockscreener
4.24
2.42%
0.10
Dopo l'orario di chiusura:
4.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$4.14
Aprire:
$4.02
Volume 24 ore:
858.24K
Relative Volume:
1.68
Capitalizzazione di mercato:
$447.25M
Reddito:
$45.44M
Utile/perdita netta:
$-35.43M
Rapporto P/E:
-13.25
EPS:
-0.32
Flusso di cassa netto:
$-25.39M
1 W Prestazione:
-0.93%
1M Prestazione:
+21.49%
6M Prestazione:
+1.92%
1 anno Prestazione:
-9.59%
Intervallo 1D:
$4.02
$4.405
Intervallo di 1 settimana:
$3.98
$4.55
Portata 52W:
$3.165
$5.545
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Confronta MXCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
4.24 | 447.25M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,111 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Shareholder Voting Rights Due to BlackRock Holdings - TipRanks
BlackRock Adjusts Stake in MaxCyte, Influencing Voting Rights - TipRanks
MaxCyte (LON:MXCT) Shares Up 3.4%Here's Why - MarketBeat
MaxCyte (LON:MXCT) Shares Up 3.4% – Here’s Why - Defense World
Fmr LLC Lowers Stake in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
MaxCyte cuts 15% of global workforce, boosts core revenue guidance - MSN
MaxCyte, Inc. Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte Announces Change in Major Shareholdings - TipRanks
Getting In Cheap On MaxCyte, Inc. (LON:MXCT) Might Be Difficult - Simply Wall St
MaxCyte Streamlines Workforce and Boosts Revenue Outlook - MSN
MaxCyte Shares Surge On Boost to Revenue-Growth Outlook - MarketWatch
MaxCyte ups core revenue guidance for 2024 as eyes 2025 cost savings - Marketscreener.com
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance Provide Update - citybiz
MaxCyte Inc slashes workforce by 15%, ups revenue forecast - TradingPedia
MaxCyte upgrades revenue guidance after operational review - ShareCast
Intech Investment Management LLC Purchases New Shares in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance - The Manila Times
MaxCyte cuts 15% of global workforce, boosts core revenue guidance (NASDAQ:MXCT) - Seeking Alpha
MaxCyte Restructures with 15% Job Cuts, Boosts 2024 Revenue Growth Outlook to 8% - StockTitan
ArrowMark Colorado Holdings LLC Purchases 169,250 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
MaxCyte Expands Stock Capital Amid Cell Therapy Growth - TipRanks
MaxCyte Sees Shift in BlackRock’s Shareholding - MSN
MaxCyte’s Voting Rights Shift with BlackRock Acquisition - MSN
MaxCyte, Inc. (NASDAQ:MXCT) Shares Purchased by Mudita Advisors LLP - MarketBeat
Electroporation Enables Efficient Antibody Discovery By Mammalian Display - BioProcess Online
Accelerate Antibody Development And Production - BioProcess Online
This MaxCyte Insider Increased Their Holding In The Last Year - Yahoo Finance
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - MSN
MaxCyte stock touches 52-week low at $3.23 amid market challenges - Investing.com Canada
Will MaxCyte's Q2 Results Surpass Market Expectations? - RTTNews
CADIAN CAPITAL MANAGEMENT, LP Expands Stake in MaxCyte Inc - GuruFocus.com
MaxCyte Celebrates 25 Years - Baystreet.ca
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics - The Manila Times
MaxCyte Marks 25 Years of Innovation with Groundbreaking Cell Therapy Breakthrough | MXCT Stock News - StockTitan
Pinterest Inc (PINS-N) QuotePress Release - The Globe and Mail
MaxCyte stock touches 52-week low at $3.27 amid market shifts - Investing.com Canada
MaxCyte stock touches 52-week low at $3.27 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
FY2024 Earnings Estimate for MaxCyte Issued By William Blair - MarketBeat
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2024 Earnings Call Transcript - MSN
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Investors ignore increasing losses at MaxCyte (LON:MXCT) as stock jumps 10% this past week - Simply Wall St
MaxCyte Files Quarterly Report, Highlights Financial Progress - TipRanks
MaxCyte’s Revenue Grows and Strategic Moves Unveiled - TipRanks
MaxCyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Constellation Energy Corp (CEG-Q) QuotePress Release - The Globe and Mail
MaxCyte Director Sells Shares Amid Active Trading - TipRanks
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maxcyte Inc Azioni (MXCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Johnston John Joseph | Director |
Dec 06 '24 |
Option Exercise |
2.93 |
505 |
1,478 |
142,455 |
| Johnston John Joseph | Director |
Dec 09 '24 |
Sale |
3.79 |
2,495 |
9,459 |
141,950 |
| Johnston John Joseph | Director |
Dec 06 '24 |
Sale |
3.70 |
505 |
1,869 |
141,950 |
| Erck Stanley C | Director |
Nov 01 '24 |
Option Exercise |
0.04 |
47,689 |
1,908 |
316,807 |
| Erck Stanley C | Director |
Nov 01 '24 |
Sale |
3.72 |
47,689 |
177,403 |
269,118 |
| Johnston John Joseph | Director |
Oct 28 '24 |
Option Exercise |
2.93 |
3,000 |
8,778 |
144,950 |
| Johnston John Joseph | Director |
Oct 28 '24 |
Sale |
3.72 |
3,000 |
11,166 |
141,950 |
| Erck Stanley C | Director |
Oct 01 '24 |
Option Exercise |
0.04 |
26,082 |
1,043 |
295,200 |
| Erck Stanley C | Director |
Oct 02 '24 |
Option Exercise |
0.04 |
21,607 |
864 |
290,725 |
| Erck Stanley C | Director |
Oct 01 '24 |
Sale |
3.78 |
26,082 |
98,590 |
269,118 |
1.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):